CCCC Current Deferred Revenue from 2010 to 2026
| CCCC Stock | USD 1.82 0.11 6.43% |
Current Deferred Revenue | First Reported 2019-12-31 | Previous Quarter 22.6 M | Current Value 17.1 M | Quarterly Volatility 7.3 M |
Check C4 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among C4 Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 230.2 K, Net Interest Income of 17.4 M or Interest Income of 17.4 M, as well as many indicators such as Price To Sales Ratio of 7.67, Dividend Yield of 0.0 or PTB Ratio of 1.09. CCCC financial statements analysis is a perfect complement when working with C4 Therapeutics Valuation or Volatility modules.
CCCC | Current Deferred Revenue | Build AI portfolio with CCCC Stock |
Analyzing C4 Therapeutics's Current Deferred Revenue over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Current Deferred Revenue has evolved provides context for assessing C4 Therapeutics's current valuation and future prospects.
Latest C4 Therapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of C4 Therapeutics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. C4 Therapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in C4 Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
CCCC Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 19,816,218 | |
| Geometric Mean | 19,507,205 | |
| Coefficient Of Variation | 20.18 | |
| Mean Deviation | 2,430,511 | |
| Median | 19,109,000 | |
| Standard Deviation | 3,998,860 | |
| Sample Variance | 16T | |
| Range | 16.3M | |
| R-Value | (0.02) | |
| Mean Square Error | 17.1T | |
| R-Squared | 0.0003 | |
| Significance | 0.95 | |
| Slope | (13,405) | |
| Total Sum of Squares | 255.9T |
CCCC Current Deferred Revenue History
About C4 Therapeutics Financial Statements
C4 Therapeutics stakeholders use historical fundamental indicators, such as C4 Therapeutics' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although C4 Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in C4 Therapeutics' assets and liabilities are reflected in the revenues and expenses on C4 Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in C4 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 16.8 M | 17.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:Check out the analysis of C4 Therapeutics Correlation against competitors. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Will Biotechnology sector continue expanding? Could CCCC diversify its offerings? Factors like these will boost the valuation of C4 Therapeutics. Projected growth potential of CCCC fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every C4 Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.67) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
Understanding C4 Therapeutics requires distinguishing between market price and book value, where the latter reflects CCCC's accounting equity. The concept of intrinsic value - what C4 Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push C4 Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between C4 Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding C4 Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, C4 Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.